IQVIA, a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, announced the launch of its Clinical Trial Financial Suite (CTFS), an AI-enabled platform orchestrating all financial aspects of clinical trials. CTFS is designed to eliminate inefficiencies created by siloed systems and fragmented processes. In contrast to other industry offerings, CTFS unifies budgeting, contracting, forecasting and payment workflows with shared data and end-to-end processes.
Health Technology Insights: Ascletis Reports ASC30 Half-Life of 36 Days, Enabling Once‑Monthly Dosing
The suite’s first module, CTFS Site Payments, brings end-to-end automation to one of the most complex trial processes. By leveraging agentic AI to set up budgets, process invoices and identify anomalies, the module frees up financial teams from repetitive manual tasks to focus their attention more productively.
IQVIA’s technology and operations experts behind CTFS have supported site and participant payments across more than 200 geographies. The solution uses advanced technology to deliver enterprise-grade scalability and security, while deploying AI to drive efficiency and acceleration to the most manual and burdensome processes. Projected customer outcomes include up to 50% reduction in processing time.
Health Technology Insights: Deerfield Group Unveils New Brand Identity and Expands Services
“With CTFS, we are building the financial backbone for modern clinical trials — unified, globally scalable and powered by agentic AI,” said Bernd Haas, Senior Vice President, Digital Products & Solutions at IQVIA. “From protocol to payments, we’re connecting and simplifying financial processes into a seamless, transparent experience for sponsors, CROs and study sites alike.”
CTFS Site Payments is slated for general commercial availability in Q1 2026, following a Q4 2025 sandbox release where early adopters will pilot the solution against their business and collaborate on their future needs.
Health Technology Insights: Immunic Secures U.S. Patent for Multiple Sclerosis Treatment Vidofludimus Calcium’s Dose Strengths
To participate in our interviews, please write to our HealthTech Media Room at sudipto@intentamplify.com
Source – businesswire
